Akebia Therapeutics, Inc. filings document the regulatory record of a commercial-stage biopharmaceutical company focused on kidney disease therapeutics. Its 8-K reports include quarterly and annual operating results, Vafseo® commercialization updates, pipeline disclosures, Regulation FD presentations, and material agreements tied to licensing, supply, and corporate facilities.
Akebia’s proxy materials describe board composition, committee assignments, director elections, executive compensation, equity plans, and shareholder voting matters. The filing record also covers governance changes, Nasdaq-listed common stock matters, risk and business disclosures related to commercial products, clinical programs, collaborations, lease obligations, and capital-structure activity.
Akebia Therapeutics, Inc. (AKBA) received a Nasdaq deficiency notice after its common stock’s closing bid price stayed below the $1.00-per-share minimum for 30 consecutive business days. The notice has no immediate effect on the stock’s listing. Akebia has until April 19, 2027, the end of its initial 180-calendar-day compliance period, to meet the requirement by closing at or above $1.00 for at least 10 consecutive business days; Nasdaq may extend that 10-day period.
If it does not regain compliance, Akebia may qualify for a second 180-calendar-day period by meeting the other stated initial listing standards and providing written notice of an intent to cure through a reverse stock split, if necessary. If no further compliance period applies or the deficiency remains at its end, Nasdaq may issue a delisting notice, which Akebia could appeal to a Nasdaq Hearings Panel. Akebia says it will evaluate options, which could include seeking a reverse stock split.
Akebia Therapeutics, Inc. (AKBA) said Nicholas Grund, its Senior Vice President and Chief Commercial Officer, plans to resign for personal reasons, effective November 6, 2026. On October 13, 2026, Grund and the company entered into a consulting agreement effective on the resignation date. He will provide consulting and advisory services through April 30, 2027, unless the company terminates the agreement with at least 10 days’ prior written notice or Grund terminates it with at least 30 days’ prior written notice. Grund will be paid an hourly rate for his services during the consulting period.
Akebia Therapeutics, Inc. CEO and President John P. Butler reported exercising stock options for 350,000 shares of common stock on August 6, 2026 at an exercise price of $0.63 per share. The derivative option position was reduced by 350,000 shares, leaving 525,000 options outstanding after the transaction. Following the exercise, Butler directly held 3,718,564 shares of common stock and indirectly held 159,928 shares through the Dorothy Butler Revocable Trust. The options were granted on January 31, 2023 and vest over four years, with 25% vested on January 31, 2024 and the remaining 75% vesting in equal quarterly installments thereafter.
Akebia Therapeutics, Inc. reported for the quarter ended June 30, 2026 total revenues of $49.1 million, compared with $62.5 million a year earlier, including product revenue of $46.8 million. Higher research and development, selling, general and administrative, and restructuring costs lifted total operating expenses to $45.0 million, resulting in a loss from operations of $6.3 million. After interest and other items, Akebia recorded a net loss of $8.9 million, or $0.03 per basic and diluted share, versus modest net income in the prior-year quarter.
As of June 30, 2026, the company held $155.5 million in cash and cash equivalents and total assets of $349.7 million, against total liabilities of $324.6 million, including a $49.6 million senior secured term loan and substantial royalty-related liabilities tied to Vafseo and Auryxia. Stockholders’ equity was $25.0 million. Akebia markets Vafseo for anemia due to chronic kidney disease and Auryxia for CKD-related indications; Auryxia lost U.S. exclusivity in March 2025, and a Teva generic entered in March 2026. Management expects existing cash and anticipated product, royalty, supply and license revenues to fund its current operating plan for at least twelve months, while acknowledging that refinancing its term loan and achieving projected Vafseo revenues are important to longer-term liquidity and that additional financing or strategic transactions may be pursued.
Akebia Therapeutics reported second quarter 2026 results with total revenues of $49.1 million, down from $62.5 million a year earlier, as Auryxia sales declined due to generic competition. Vafseo net product revenue increased to $21.3 million from $13.3 million, while Auryxia revenue fell to $25.5 million from $47.2 million. The company recorded a net loss of $8.9 million, compared with net income of $0.2 million in the prior-year quarter. Cash and cash equivalents were $155.5 million as of June 30, 2026.
Commercially, more than 10,500 patients were on Vafseo in the quarter, with prescribers rising to about 1,200. An interim analysis of the 2,116-patient VOICE trial showed statistically significant improved safety outcomes for Vafseo versus an ESA (win odds 1.16; 95% CI 1.06–1.28; p=0.0016). Akebia also initiated a Phase 2 open-label basket trial of ebribafusp for several rare kidney diseases, continued enrolling a Phase 2 trial of praliciguat in FSGS, and strengthened Vafseo’s patent estate with a new Orange Book–listed patent and potential patent term extension. Operating expenses included $1.9 million of restructuring charges related to commercial reorganization.
Akebia Therapeutics, Inc. SVP, CFO, CBO & Treasurer Erik Ostrowski reported an open-market sale of 56,019 shares of common stock at $1.11 per share on June 29, 2026. According to the footnote, this was an automatic “sell to cover” transaction to satisfy tax withholding on vesting restricted stock units granted on June 28, 2024, executed under durable instructions adopted on September 8, 2025. After the sale, he directly holds 616,616 shares of Akebia common stock.
Akebia Therapeutics reported interim results from the VOICE trial of Vafseo in dialysis patients with anemia due to chronic kidney disease. The randomized, active-controlled safety study in 2,116 patients met predefined stopping criteria, showing Vafseo was both non-inferior and superior to an erythropoiesis-stimulating agent on the primary composite endpoint of all-cause mortality and hospitalization.
The interim analysis as of June 1, 2026 showed a win odds of 1.16 (95% CI 1.06, 1.28, p=0.0016). Hospitalizations were lower with Vafseo at 1.11 versus 1.23 per patient-year, with an incidence rate ratio of 0.90 (95% CI 0.824, 0.988), while mortality rates were similar between groups at 8.77% versus 8.78% per 100 patient-years.
Akebia Therapeutics submitted a Form 144 notice related to Common Stock tied to the vesting of restricted stock units on 06/28/2026. The filing lists 56,019 in connection with the equity compensation event and references Nasdaq and the date 06/29/2026.
Akebia Therapeutics director Myles Wolf received equity awards as part of non-employee director compensation. He was granted 35,700 shares of Common Stock in the form of restricted stock units and a stock option for 53,600 shares at an exercise price of $1.02 per share. Both the RSUs and the option vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholder meeting after the grant, if that occurs sooner, subject to his continued service. Following the award, he directly owns 169,081 Common Shares and holds the newly granted option for 53,600 underlying shares.
Akebia Therapeutics director Cynthia Smith received new equity awards as part of non-employee director compensation. She was granted 35,700 restricted stock units and an option for 53,600 shares of common stock at an exercise price of $1.02 per share. Both awards vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the next annual stockholder meeting, if she continues serving. After the RSU grant, she directly holds 196,633 common shares.